This patent relates to a method of treating IgG4-related disease comprising administration of an Interleukin-4 inhibitor/antagonist, an IL-4 receptor alpha inhibitor, or a compound which blocks assembly of IL-4 receptor alpha with IL-13 receptor alpha. The method of treating IgG4-related disease may comprise administration of a JAK inhibitor. The method of treating IgG4-related disease may comprise administration of duplimab and/or pitrakinra.
展开▼